N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists
申请人:PFIZER INC.
公开号:EP1160248A1
公开(公告)日:2001-12-05
Isoxazoles of formula (I) below have good affinity for endothelin receptors, and are selective for ETA over ETB.
wherein
R1 is either
a)a phenyl group; or
b)an optionally benzo-fused 5- or 6-membered heterocyclic group with one to three heteroatoms in the heterocyclic ring, which heteroatoms are independently selected from N, O and S; or
CHR6CHR7Ph, CR6:CR7Ph;
each of which groups (a) (b) and (c) is optionally substituted by up to three substituents each independently selected from:
i)halo;
ii)C1-6 alkyl optionally substituted by OH, halogen, NR4R5 OCOR4 or CO2R4;
iii)CN;
iv)O(C1-8 alkyl optionally substituted by one or more halogen); and
v)CO2R4;
R2 is aryl1 or het1,
R3 is H, C1-6 alkyl, C(O)R4, CONHaryl1, CONHhet1, aryl1 and het1
Such compounds are useful in the treatment of conditions mediated by endothelin.
下式(I)的异噁唑对内皮素受体具有良好的亲和力,对 ETA 的选择性高于 ETB。
其中
R1 是
a)苯基;或
b)可选的苯并融合的 5 或 6 元杂环基团,杂环中含有 1 至 3 个杂原子,杂原子独立选自 N、O 和 S;或
CHR6CHR7Ph, CR6:CR7Ph;
(a)(b)和(c)基团中的每一个基团可任选被最多三个各自独立选自以下各项的取代基取代:
i)卤代
C1-6烷基,可任选被 OH、卤素、NR4R5 OCOR4 或 CO2R4 取代;
iii)CN;
iv)O(任选被一个或多个卤素取代的 C1-8 烷基);以及
v)CO2R4;
R2 是芳基1 或烷基1、
R3 是 H、C1-6 烷基、C(O)R4、CONHaryl1、CONHhet1、芳基1 和 het1。
此类化合物可用于治疗由内皮素介导的疾病。